Literature DB >> 19055479

O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease.

Stephen B Harvey1, Yan Zhang, Joshua Wilson-Grady, Teresa Monkkonen, Gary L Nelsestuen, Raj S Kasthuri, Michael R Verneris, Troy C Lund, E Wesley Ely, Gordon R Bernard, Harald Zeisler, Monika Homoncik, Bernd Jilma, Therese Swan, Todd A Kellogg.   

Abstract

The glyco-isoforms of intact apolipoprotein C3 (ApoC3) were used to probe glycomic changes associated with obesity and recovery following bariatric surgery, liver diseases such as chronic hepatitis C (CHC) and alcoholic liver cirrhosis, as well as severe, multiorgan diseases such as sepsis and graft vs host disease (GVHD). ApoC3 glyco-isoform ratios responded to unique stimuli that did not correlate with serum lipids or with other blood components measured in either a control population or a group of extremely obese individuals. However, glyco-isoform ratios correlated with obesity with a 1.8-fold change among subjects eligible for bariatric surgery relative to a nonobese control population. Bariatric surgery resulted in rapid change of isoform distribution to that of nonobese individuals, after which the distribution was stable in each individual. Although multiple simultaneous factors complicated effector attribution, the isoform ratios of very obese individuals were nearly normal for diabetic individuals on metformin therapy. Glyco-isoform ratios were sensitive to liver diseases such as chronic hepatitis C and alcoholic liver cirrhosis. The correlation coefficient with fibrosis was superior to that of current assays of serum enzyme levels. Diseases of pregnancy that can result in liver damage, HELLP syndrome and pre-eclampsia, did not alter ApoC3 glyco-isoform ratios. Early after umbilical cord blood transplantation the isoform ratios changed and returned to normal in long-term survivors. Larger changes were observed in persons who died. GVHD had little effect. Persons with severe sepsis showed altered ratios. Similar cut-points for mortality (3.5-fold difference from controls) were found for UCBT and sepsis. Similar values characterized liver cirrhosis. Overall, while changes of glyco-isoform ratios occurred in many situations, individual stability of isoform distribution was evident and large changes were limited to high-level disease. If ratio changes associated with obesity are found to document a risk factor for long-term outcomes, the information provided by glyco-isoform ratio changes may provide important, novel information for diagnostic, prognostic and therapy response to metabolic conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19055479     DOI: 10.1021/pr800751x

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  16 in total

1.  Investigation of plasma biomarkers in HIV-1/HCV mono- and coinfected individuals by multiplex iTRAQ quantitative proteomics.

Authors:  Vivekananda Shetty; Pooja Jain; Zacharie Nickens; Gomathinayagam Sinnathamby; Anand Mehta; Ramila Philip
Journal:  OMICS       Date:  2011-10

2.  Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry.

Authors:  Matthew T Mazur; Helene L Cardasis; Daniel S Spellman; Andy Liaw; Nathan A Yates; Ronald C Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-13       Impact factor: 11.205

3.  Longitudinal analysis of maternal plasma apolipoproteins in pregnancy: a targeted proteomics approach.

Authors:  Shannon K Flood-Nichols; Deborah Tinnemore; Mark A Wingerd; Ali I Abu-Alya; Peter G Napolitano; Jonathan D Stallings; Danielle L Ippolito
Journal:  Mol Cell Proteomics       Date:  2012-10-10       Impact factor: 5.911

Review 4.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

5.  Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.

Authors:  Saulo Mendoza; Olgica Trenchevska; Sarah M King; Randall W Nelson; Dobrin Nedelkov; Ronald M Krauss; Hussein N Yassine
Journal:  J Clin Lipidol       Date:  2016-12-28       Impact factor: 4.766

6.  Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation.

Authors:  Joseph McGuirk; Gang Hao; Weijian Hou; Sunil Abhyankar; Casey Williams; Weisi Yan; Jianda Yuan; Xiuqin Guan; Robert Belt; Shaun Dejarnette; Jeffery Wieman; Ying Yan
Journal:  J Hematol Oncol       Date:  2009-04-20       Impact factor: 17.388

7.  Proteomics reveals age-related differences in the host immune response to sepsis.

Authors:  Zhiyun Cao; Sachin Yende; John A Kellum; Derek C Angus; Renã A S Robinson
Journal:  J Proteome Res       Date:  2013-12-04       Impact factor: 4.466

8.  Mass spectrometric identification of aberrantly glycosylated human apolipoprotein C-III peptides in urine from Schistosoma mansoni-infected individuals.

Authors:  Crina I A Balog; Oleg A Mayboroda; Manfred Wuhrer; Cornelis H Hokke; André M Deelder; Paul J Hensbergen
Journal:  Mol Cell Proteomics       Date:  2010-01-13       Impact factor: 5.911

Review 9.  Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes.

Authors:  K J Neff; T Olbers; C W le Roux
Journal:  BMC Med       Date:  2013-01-10       Impact factor: 8.775

10.  Targeted Measurements of O- and N-Glycopeptides Show That Proteins in High Density Lipoprotein Particles Are Enriched with Specific Glycosylation Compared to Plasma.

Authors:  Muchena J Kailemia; Wanghui Wei; Khoa Nguyen; Elizabeth Beals; Lisa Sawrey-Kubicek; Christopher Rhodes; Chenghao Zhu; Romina Sacchi; Angela M Zivkovic; Carlito B Lebrilla
Journal:  J Proteome Res       Date:  2017-12-27       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.